BJMO - volume 8, issue 5, november 2014
Mugdha Deo PhD, F. Cornélis MD, J-F. Baurain MD, PhD
(BELG J MED ONCOL 2014;8(4):136–42)
Read moreBJMO - volume 8, issue 5, november 2014
T. Vermassen PhD, S. Rottey MD, PhD
From the 26th till the 30th of September, Madrid was host for the 39th annual congress of the European Society of Medical Oncology (ESMO). The theme of this years’ meeting, that was hosted at the IFEMA – Feria de Madrid, was ‘Precision Medicine in Cancer Care. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.
(BELG J MED ONCOL 2014;8(4):143–6)
Read moreBJMO - volume 8, issue 5, november 2014
J. Kerger MD
Notwithstanding the fact that no breaking, practice-changing studies were presented in the sessions devoted to gynaecological cancers at this years’ annual ESMO meeting, the strong trend towards targeted therapies was confirmed, in accordance with the general theme of “precision medicine” at this meeting.
(BELG J MED ONCOL 2014;8(4):147–51)
Read moreBJMO - volume 8, issue 5, november 2014
B. Hiddinga MD, J.P. Van Meerbeeck MD, PhD
This report will highlight 10 important studies presented during ESMO 2014, and 4 small but promising future directions in the treatment of NSCLC. The presidential symposium featured two negative studies in a large cohort of non-small cell lung cancer (NSCLC) patients: the MAGRIT and IMPRESS. The other topics include immunotherapy, targeted treatment and biomarkers, development of new drugs in ALK-EML rearranged NSCLC, and prevention of cachexia in NSCLC. Lastly, an important study in malignant pleural mesothelioma (MPM) was presented.
(BELG J MED ONCOL 2014;8(4):152–7)
Read moreBJMO - volume 8, issue 5, november 2014
M. Peeters MD, PhD, K. Papadimitriou MD, PhD
From 26 till 30 September 2014, the 30th yearly ESMO meeting took place in Madrid. The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ This report will highlight the key studies presented during the meeting, with special focus on gastrointestinal cancer.
(BELG J MED ONCOL 2014;8(4):158–62)
Read moreBJMO - volume 8, issue 5, november 2014
L. Decoster MD, PhD
The 2014 annual meeting of the European Society for Medical Oncology (ESMO) featured a number of interesting studies in endocrine and neuroendocrine oncology. This report will first focus on two presentations regarding lenvatinib in the treatment of thyroid cancers. In addition to this, the final OS of the RADIANT-3 study, evaluating everolimus in patients with advanced pancreatic neuroendocrine tumours (NET), will be summarized. The last part of the report will focus on the molecular profiling of NETs and discusses a study assessing the quality of life in NET patients using lanreotide autogel.
(BELG J MED ONCOL 2014;8(4):163–5)
Read moreBJMO - volume 8, issue 5, november 2014
H. Wildiers MD, PhD, Tom Feys MBA, MSc
(BELG J MED ONCOL 2014;8(4):166–70)
Read more
Top
